| Literature DB >> 27089351 |
Nuno Pombo1,2,3, Nuno Garcia4,5,6, Kouamana Bousson7, Susanna Spinsante8, Ivan Chorbev9.
Abstract
BACKGROUND: Mobile and web technologies are becoming increasingly used to support the treatment of chronic pain conditions. However, the subjectivity of pain perception makes its management and evaluation very difficult. Pain treatment requires a multi-dimensional approach (e.g., sensory, affective, cognitive) whence the evidence of technology effects across dimensions is lacking. This study aims to describe computerised monitoring systems and to suggest a methodology, based on statistical analysis, to evaluate their effects on pain assessment.Entities:
Keywords: chronic pain; mhealth; pain assessment; pain diaries; pain scales
Mesh:
Year: 2016 PMID: 27089351 PMCID: PMC4847077 DOI: 10.3390/ijerph13040415
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Studies characteristics.
| Study/Year | Population Participants (Mean Age, SD) | Patient Home | Data | Quality | ||
|---|---|---|---|---|---|---|
| As a Complement to the System | Collected through the Use of System | Transmission | ||||
| Allen [ | 157 (61.7 ± 10.6) | Yes | Pain intensity (VAS), immediately after waking, then approximately every 2 h throughout the day (in order to complete at least 7 pain ratings per day) and immediately before going to sleep (to recall the average pain during the day) | NR | L | |
| Anatchkova [ | 100 | No | Pain intensity (NRS), computer adaptive dynamic assessment of The Chronic Pain Impact Item Bank [ | NR | L | |
| Axen [ | 262 (44) | Yes | Pain intensity (NRS), once a week using SMS | Instant | L | |
| Badr [ | 54 patients (49.4 ± 10.8) | Yes | Instant | L | ||
| Baron-Mahn [ | 2094 painful radiculopathy (59.4 ± 14.4) | No | MOS-SS, PHQ, PD-Q and pain location (pinpointed in 3D mannequin) in the medical appointment | Delayed | L | |
| Broderick-Schneider [ | 83 (56.2 ± 11.1) | Yes | SF-36, BPI, BFI, MPQ, 7 times per day during the patients’ waking hours | Delayed | L | |
| Clauw [ | 399 IG 100 mg/day (49.5 ± 10.9) | Yes | Instant | H | ||
| Connelly [ | 9 (12.3 ± 3.4) | Yes | Delayed | L | ||
| Gaertner [ | 24 (49.9 ± 15.1) Crossover randomized between IG and CG | Yes | Pain intensity (NRS), once a day and symptom assessment (fatigue, nausea, dyspnea, weakness…), once a week | Delayed | L | |
| Ghinea [ | 45 (46.1) | Yes | Pain intensity (VAS) and location (pinpointed in 3D mannequin), 3 times a day | Instant | L | |
| Giske [ | 50 (50.0 ± 11.0) | Yes | Pain intensity (NRS), 5 times a day between 9 a.m. and 9 p.m., using SMS | Instant | L | |
| Heiberg [ | 38 (58.4 ± 12.9) | Yes | Instant | H | ||
| Jamison [ | 20 IG (42.1 ± 5.0) | Yes | Pain intensity (VAS) and pain ratings of the previous 16 waking hours, once a day (bedtime) | Delayed | H | |
| Jamison [ | 24 (34.4) | No | Pain intensity (VAS) | Delayed | L | |
| Jamison [ | 21 (42.0 ± 4.9) | Yes | Pain intensity (VAS), at least once a day | Delayed | H | |
| Jamison-Wasan [ | 21 IG ED + CBT (47.0 ± 7.8) | Yes | BPI, pain location once a month at clinic visit Wasan’s study, also includes four questions to assess craving for prescription opioids over the past 24 h (14 days ED at patients' home) | Delayed | H | |
| Jespersen [ | 188 (44.4 ± 9.0) | Yes | AMS, IPAQ, once a week using SMS | Instant | H | |
| Koroschetz [ | 1623 painful diabetic neuropathy (61.9 ± 13.0) | No | MOS-SS, PHQ, PD-Q and pain location (pinpointed in 3D mannequin) in the medical appointment | Delayed | L | |
| Kvien [ | 30 (61.6) | No | Pain intensity (VAS), fatigue, and patient global evaluation of their disease, RADAI, MHAQ, SF-36, at 2 medical appointments | Instant | L | |
| Lewandowski [ | 39 chronic pain (15.3 ± 1.5) | Yes | Sleep quality (NRS) in the morning and pain intensity (NRS) in the evening. Integrated with wrist actigraphy to monitorize the sleep | Delayed | L | |
| Levin [ | 24 | Yes | Pain intensity (NRS), location, duration reported via automated speech telephony delivery (a.k.a automated speech recognition) | Instant | L | |
| Li [ | 60 (69.0 ± 10.0) | Yes | MPQ-SF, 8 times per day (hourly between 2 and 9 p.m.) | Delayed | H | |
| Lind [ | 12 (67.5 ± 7.8) | Yes | Pain intensity (VAS), 3 times a day (8 a.m., 1 p.m., 8 p.m.) | Instant | L | |
| Litt [ | 32 IG | Yes | Pan location, unpleasantness experienced, perceived control over pain, catastrophization and coping, 4 times per day (from 8 a.m. to 10 p.m.). Interactive voice recording was used | Instant | H | |
| Luckmann [ | 4 | Yes | Pain intensity (NRS), location, activity and treatment completed each 2–4 waking hours. Acute pain registered when happens. Sleep report in the morning and end of day report before sleep. Data integration with PHR | Instant | L | |
| Marceau [ | 67 IG (48.5 ± 11.6) | No | BPI at each monthly clinic visit. Pre and post-treatment and 5-month follow up: BPI, PCS, ODI, CES-D | Instant | H | |
| McClellan [ | 9 IG | Yes | Pain intensity at morning and evening (10-point Likert scale), pain location, sleep quality, and functional limitations once a day | Instant | H | |
| Oerlemans [ | 37 IG (35.9 ± 11.7) | Yes | Pain intensity (5-point Likert scale) 3 times per day (morning, afternoon and evening). Sleep quality and intended activities for the day. (morning), accomplished activities, cognitions, and feelings (afternoon), and satisfaction with activity level and achievements of that day (evening) | Instant | H | |
| Okifuji [ | 81 (28.8 ± 6.2) | Yes | Overall pain (7-point Likert scale), fatigue, head pain, emotional distress, abdominal pain, sense of relaxation, muscle pain, and sense of swelling, 3 times per day (morning, early afternoon, late afternoon) | Delayed | L | |
| Page [ | 14 (65.1) | No | MPQ, in the medical appointment | Delayed | L | |
| Palermo [ | 30 IG (12.3 ± 2.4) | Yes | Pain intensity (Faces pain scale [ | Delayed | H | |
| Peters [ | 80 (40.6 ± 6.7) | Yes | Pain intensity (7-point scale) and signal controlled diary (items: pain cognition, pain coping, sleep quality...), 4 times per day between 8 a.m. and 9:30 p.m. | Delayed | H | |
| Roelofs [ | 40 (46.4 ± 9.9) | Yes | Pain intensity (PVAQ), TSK, 8 times per day between 8 a.m. (weekend 9 a.m.) and 10 p.m. | Delayed | L | |
| Schurman [ | 10 IG | Yes | Pain intensity (Faces pain scale Revised), once per day (bedtime) | Delayed | H | |
| Sorbi [ | 5 | Yes | Pain intensity (VAS). 1st test run: 4–5 times per day. 2nd test run: 2–3 times per day | Instant | L | |
| Stinson [ | Study 1 76 (13.4 ± 2.5) | Yes | Pain intensity, pain unpleasantness, pain’s interference with aspects of quality of life and other symptoms (e.g., stiffness and fatigue) (VAS), 3 times per day (upon waking, after school, and before bed) | Instant | H | |
| Stinson [ | 24 children (5.9 ± 0.9) | No | Pain intensity: faces pain scale (children), NRS (youth), in the medical appointment | Instant | H | |
| Stone [ | 40 IG (43.0 ± 9.0) | Yes | BPI, PD-IIP, HAQ, 3 times per day (10 p.m., 4 a.m., 8 a.m.) | Delayed | H | |
| Stone-Kelly [ | 22 IG 3 prompts/day (49.0 ± 10.7) | Yes | Pain intensity (VAS), and other questions related to sensory, affective and physical aspects, 3, 6 or 12 times a day. Kelly’s study includes all the IGs | Delayed | H | |
| Turner [ | 61 IG (39.3 ± 11.1) | Yes | Pain intensity (NRS), pain-related activity interference, jaw use limitations, and several questions adapted from CSQ, SOPA, PCS, and DCI, 3 times per day (morning, afternoon, and evening) | Delayed | H | |
| Wallasch [ | 545 (43.1 ± 12.9) | Yes | MIDAS, GCPS, HADS, SF-12 | Delayed | L | |
| Weering [ | 16 (40.7 ± 13.8). | Yes | Pain intensity (VAS), 3 times a day (noon, 4 p.m., 8 p.m.). Integration with Body Area Network (BAN) | Instant | L | |
| Younger [ | 10 (46.5 ± 10.3) | Yes | Fibromyalgia severity, average pain intensity, highest pain, and other symptoms (fatigue, sadness, stress, sleep quality, ability to think and remember…), once a day (night) | NR | L | |
| Berman [ | 41 IG (64.3) | Pain intensity (BPI), after logon and before logoff in the site | H | |||
| Buhrman [ | 22 IG (43.5 ± 10.3) | Pain intensity (VAS), 3 times per day (morning, noon and evening). PAIRS, MPI, CSQ and HADS once a week | H | |||
| Devineni [ | 39 IG (43.6 ± 12.0) | Frequency, duration, and severity of pain, once a day | H | |||
| Hicks [ | 25 IG (12.1 ± 2.0) | Pain intensity (NRS), 4 times per day | H | |||
| Hunt [ | 28 IG (39.0 ± 10.0) | GSRS-IBS, IBS-QoL, ASI, GAD-Q and CPSQ, conducted at pre-and post-treatment and 3-month follow-up | H | |||
| Kristjansdottir [ | 6 (36.3) | Pain intensity, interference of pain, planned and achieved activities, feelings, pain-related fear, avoidance, catastrophizing and acceptance, | L | |||
| Ljótsson [ | 42 IG (36.4 ± 10.1) | GSRS-IBS, IBS-QoL, VSI, MADRS-S and SDS conducted at pre-and post treatment. 3-month follow up: VSI, IBS-QoL and 2 weekly GSRS-IBS | H | |||
| Lorig [ | 422 IG (52.2 ± 10.9) | Pre and post treatment, and 6/12 months follow up: pain intensity and fatigue (NRS), distress, activities limitations, disabilities and HAQ | H | |||
| Palermo [ | 26 IG (14.3 ± 2.1) | Pain intensity (NRS), CALI | H | |||
| Ruehlman [ | 162 IG (19~78) 143 CG (19~78) | CES-D, DASS, PCP-S and PCP-EA at pre-treatment, 7-weeks and 14-weeks follow-up | H | |||
| Strom [ | 20 IG (41.5) | H | ||||
| Williams [ | 59 IG (50.2 ± 12.3) 59 | SF-36, BPI, MFI, MOS-SS, CES-D, STPI and PGIC at pre and post-treatment | H | |||
IG: Intervention Group; CG: Control Group; Q:Quality (H: Above average quality L: Below average quality); NR: Not Reported; ED: Electronic Diary; CBT: Cognitive-behavioural Therapy. ABC: Addiction Behaviours Checklist [117]; AMS: Analysys of Musculoskeletal Symptoms [118]; ARCS: Adult Responses to Children’s Symptoms Questionnaire [119]; ASEX: Arizona Sexual Experience [120]; ASI: Anxiety Sensitivity Index [121]; BASC: Behaviour Assessment System for Children [122]; BDI: Beck Depression Inventory [123]; BDI-II: BDI revised; BFI: Brief Fatigue Inventory [124]; BPI: Brief Pain Inventory [125]; BSI: Brief Symptom Inventory [126]; CALI: Child Activity Limitations Interview [127]; CALQ: Child Activity Limitations Questionnaire [128]; CES-D: Center for Epidemiological Studies Depression Scale [129]; CPAQ: Chronic Pain Acceptance Questionnaire [130]; CPEQ: Comprehensive Pain Evaluation Questionnaire [131]; CPSQ: Consequences of Physical Sensations Questionnaire [132]; COMM: Current Medication Misuse Measure [133]; CSI: Children’s Somatisation Inventory [134]; CSQ: Coping Strategies Questionnaire [135]; CSFBD: Cognitive Scale for Functional Bowel Disorders [136]; DASS: Depression Anxiety Stress Scale [137]; DCI: Daily Coping Inventory [138]; EQ5D: Euro-QoL 5 [139]; FIQ: Fibromyalgia Impact Questionnaire [140]; GAD-Q: Generalized Anxiety Disorder Questionnaire [141]; GCPS: Graded Chronic Pain Scale [142]; GSRS-IBS: Gastrointestinal Symptom Rating Scale—Irritable Bowel Syndrome [143]; IBS-QoL: Irritable Bowel Syndrome Quality of Life [144]; IPAQ: International Physical Activity Questionnaire [145]; HADS: Hospital Anxiety and Depression Scale [146]; HAQ: Health Assessment Questionnaire [147]; HDI: Headache Disability Inventory [148]; HDM: Healthy Days Measures [149]; HSCL-25: Hopkins Symptom Check List [150]; HSQ: Headache Symptom Questionnaire [151]; MADRS-S: Montgomery Åsberg Depression Rating Scale-Self report [152]; MASQ: Multiple Ability Self-Report Questionnaire [153]; MDHAQ: Multidimensional Health Assessment Questionnaire [154]; MFI: Multidimensional Fatigue Inventory [155]; MHAQ: Modified Health Assessment Questionnaire [156]; MIDAS: MIgraine Disability Assessment Score [157]; MINI: Mini-International Neuropsychiatric Interview [158]; MLPC: Multidimensional Locus of Pain Control [159]; MOS-SS: Medical Outcomes Study Sleep Scale [160]; MPI: Multidimensional Pain Inventory [161]; MPQ: McGill Pain Questionnaire [162]; MPQ-SF: MPQ-Short Format; NRS: Numeric Rating Scale [163]; ODI: Oswestry Disability Index [164]; PAIRS: Pain Impairment Rating Scale [165]; PANAS: Positive and Negative Affect Schedule [166]; PANAS-C: PANAS for Children; PAQ: Pain Awareness Questionnaire [41]; PCP-EA: Profile of Chronic Pain Extended Assessment [167]; PCP-S: Profile of Chronic Pain: Screen [168]; PCQ: Pain Coping Questionnaire [169]; PCS: Pain Catastrophizing Scale [170]; PD-IIP: Personality Disorders Scale of the Inventory of Interpersonal Problems [171]; PD-Q: painDETECT questionnaire [172]; PDI: Pain Disability Index [173]; PDQ-39: Parkinson’s Disease Questionnaire-39 [174]; PDUQ: Prescription Drug Use Questionnaire [175]; PedsQL: Pediatric Quality of Life Inventory [176]; PGIC: Patient Global Impression of Change [177]; PHQ: Patient Health Questionnaire [178]; PSEQ: Pain Self-efficacy Questionnaire [179]; PVAQ: Pain Vigilance and Awareness Questionnaire [180]; QBPDS: Quebec Back Pain Disability Scale [181]; RADAI: Rheumatoid Arthritis Disease Activity Index [182]; RCADS: Revised Child Anxiety and Depression Scale [183]; RMDQ: Roland Morris Disability Questionnaire [184]; SCL-90: Symptom Checklist-90 [185]; SDS: Sheehan Disability Scale [186]; SF-36: MOS 36-ltem short-form [187] (SF-12 are a short version of SF-36); SOAPP-R: Screener and Opioid Assessment for Pain Patients-Revised [188]; SoC: Stage of Change [189]; SOPA: Survey of Pain Attitudes [190] ; STAI: State-Trait Anxiety Inventory [191]; STPI: State-Trait Personality Inventory [192]; TSK: Tampa Scale for Kinesiophobia [193]; UPDRS: Unified Parkinson’s Disease Rating Scale [194]; VAS: Visual Analogue Scale [195]; VSI: Visceral Sensitivity Index [196].
Risk of bias assessment.
| Study/Year | Sequence Generation | Allocation Concealment | Blinding of Participants, Personnel and Outcome Assessors | Incomplete Outcome Data | Free of Selective Outcome Reporting | Free of Other Sources of Bias |
|---|---|---|---|---|---|---|
| Berman [ | Yes | No | No | Yes | Yes | No |
| Buhrman [ | Yes | Yes | No | Yes | Yes | Yes |
| Devineni [ | No | Yes | No | Yes | Yes | Yes |
| Hicks [ | Yes | Yes | No | No | Yes | Yes |
| Hunt [ | Yes | Yes | No | No | Yes | No |
| Litt [ | Yes | Yes | No | Unclear | Yes | Yes |
| Ljótsson [ | Yes | Yes | No | Unclear | Yes | Yes |
| Lorig [ | Yes | Yes | No | No | Yes | Yes |
| Marceau [ | Yes | Yes | No | No | Yes | Yes |
| Oerlemans [ | Yes | Yes | No | Unclear | Yes | No |
| Palermo [ | Yes | Yes | No | Yes | Yes | Yes |
| Ruehlman [ | Yes | Yes | No | Yes | Yes | No |
| Schurman [ | Yes | Yes | No | Yes | Yes | Yes |
| Strom [ | Yes | Yes | No | Yes | Yes | No |
| Turner [ | No | Yes | No | Yes | Yes | Yes |
| Williams [ | Yes | Yes | No | Unclear | Yes | Yes |
Figure 1Example of a distribution curve when technology and pen-and-paper are qualitatively equivalent.
Figure 2Example of a distribution curve when technology and pen-and-paper are qualitatively different.
Comparison between pen-and-paper, and mobile and web technology using pre and post treatment results by study and overall.
| Pain intensity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study | Variable | Technology | Pen and Paper | Technology | Pen and Paper | Favourable To | ||||
| Pre Treatment | Post Treatment | Pre Treatment | Post Treatment | Aggregated Value | SD | Aggregated Value | SD | |||
| Value (SD) | Value (SD) | Value (SD) | Value (SD) | |||||||
| Berman [ | BPI (mean) | 52 (19.40) | 45.60 (18.30) | 54.30 (17.40) | 47.30 (18.40) | 48.61 | 13.31 | 51 | 12.64 | Technology |
| Buhrman [ | Pain (mean) | 37.40 (18.20) | 34.30 (16.80) | 44.4 (14.20) | 39.6 (16.30) | 35.73 | 12.34 | 42.33 | 10.71 | Technology |
| MP—pa in severity | 63.33 (31.67) | 40 (18.33) | 83.33 (28.33) | 53.33 (13.33) | 45.86 | 15.87 | 58.77 | 12.06 | Technology | |
| Devineni [ | Headache pain | 31.80 (17) | 18.60 (13) | 35.50 (15.50) | 30.60 (14.70) | 23.47 | 10.33 | 32.92 | 10.67 | Technology |
| Hicks [ | Pain (mean) | 48 (13) | 34 (24) | 43 (16) | 47 (22) | 44.82 | 11.43 | 44.38 | 12.94 | Pen-and-Paper |
| Litt [ | MPI (mean) | 43.83 (21) | 20.50 (16.33) | 35.17 (14.33) | 25 (22.67) | 29.29 | 12.89 | 32.26 | 12.11 | Technology |
| Ljótsson [ | Pain | 65 (42.50) | 35 (37.50) | 60 (37.50) | 60 (40) | 48.13 | 28.12 | 60 | 27.36 | Technology |
| Lorig [ | Pain | 65.30 (22.70) | 58.60 (24.40) | 63.70 (22.20) | 63.40 (23.10) | 62.19 | 16.62 | 63.56 | 16.01 | Technology |
| Palermo [ | Pain | 54.50 (22.50) | 35.40 (24.20) | 51.70 (16.50) | 47.60 (18.40) | 45.64 | 16.48 | 49.87 | 12.28 | Technology |
| Retrospective pain | 66.30 (18.70) | 49.60 (21.80) | 61.60 (18.40) | 54.50 (20.40) | 59.22 | 14.19 | 58.42 | 13.66 | Pen-and-Paper | |
| Ruehlman [ | PCP-S—pain severity | 76.47 (9.72) | 71.10 (12.94) | 74.78 (10.91) | 71.66 (13.28) | 74.53 | 7.77 | 73.52 | 8.43 | Pen-and-Paper |
| Turner [ | Pain (mean) | 43 (22) | 39 (24) | 43 (19) | 40 (22) | 41.17 | 16.22 | 41.72 | 14.38 | Technology |
| Williams [ | BPI—pain severity | 51 (14) | 43 (16) | 49 (14) | 49 (15) | 47.53 | 10.54 | 49 | 10.23 | Technology |
| value | ||||||||||
| alpha | 23.04 | 25.82 | 20.79 | 24.38 | ||||||
Figure 3Selected studies.